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Abstract
Previous studies on the usefulness of C-reactive protein (CRP) in patients with community-acquired pneumonia (CAP) have yielded
somewhat inconsistent results. Our aim was to assess the value of CRP in estimating the severity and complications of CAP. CRP levels
during the ﬁrst 5 days of hospitalization were measured in 384 adult patients with CAP, and the data were evaluated using comprehen-
sive statistical analyses. Signiﬁcantly higher CRP levels on admission were detected in Pneumonia Severity Index (PSI) classes III–V than
in classes I and II (p <0.001). An increment of 50 mg/L CRP on admission was associated with a 1.22-fold odds for a patient to be in
PSI classes III–V as compared with classes I and II (OR 1.22, 95% CI 1.11–1.34; p <0.001). CRP levels were signiﬁcantly higher in bacte-
raemic pneumonia than in non-bacteraemic pneumonia (p <0.001). An increment of 50 mg/L CRP was associated with a 1.67-fold odds
for a patient to be bacteraemic (OR 1.67, 95% CI 1.46–1.92; p <0.001). CRP levels >100 mg/L on day 4 after the admission were signif-
icantly associated with complications (p <0.01). There was a trend for an association between the level of CRP on admission and the
time to reach clinical stability (p <0.01). In conclusion, CRP may be valuable for revealing the development of complications in CAP. It
may also be useful to assess the disease severity, thus being complementary to the assessment of the PSI. In our patients, high CRP lev-
els were associated with a failure to reach clinical stability.
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Introduction
Many studies have shown the clinical utility of C-reactive pro-
tein (CRP) concentration as an acute-phase reactant in
patients with various infections, including septicaemia, meningi-
tis and infective endocarditis [1–8]. Previous studies have also
shown that the CRP level may contribute to establishing the
diagnosis of community-acquired pneumonia (CAP) [9–13]. In
addition, the use of CRP as a tool in the aetiological diagnosis
of CAP has been investigated in a number of studies, but the
results have been discordant [11,14–18]. Similarly, the results
of the studies evaluating the use of CRP as a prognostic factor
have been somewhat inconsistent [14,17–23], although the
CRP levels have been found to be higher in bacteraemic pneu-
monia than in non-bacteraemic pneumonia [14,15,17].
In the present study, we sought to evaluate whether the
level of CRP on admission could be used to estimate the
severity and potential aetiology of CAP. We also assessed
whether the CRP levels during the ﬁrst days of hospitaliza-
tion were associated with the clinical stabilization of the
patient or the development of complications in CAP.
Patients and Methods
The patients included in this study are the same as those
included in a prospective clinical study of the aetiology of
CAP in 384 consecutive hospitalized patients treated at the
Department of Infectious Diseases, Turku University Hospi-
tal, Turku, Finland, between December 1999 and 2004 [24].
The diagnostic criteria for CAP included a new inﬁltrate on
the chest radiograph in a patient with either fever or clinical
signs/symptoms of lower respiratory tract infection, or both
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[24]. Exclusion criteria included immunosuppression of the
patient, an emerging alternative diagnosis during the follow-
up, pneumonia caused by tuberculosis or aspiration, and hos-
pitalization within the previous 10 days.
The microbiological evaluation included blood culture,
sputum culture, urine antigen tests for Streptococcus pneumo-
niae and Legionella pneumophila, detection of a respiratory
virus antigen in a nasopharyngeal sample, PCR tests for Myco-
plasma pneumoniae, Chlamydophila pneumoniae, L. pneumophila,
inﬂuenza A virus and inﬂuenza B virus from a throat swab
sample, and detection of antibodies against M. pneumoniae,
C. pneumoniae and L. pneumophila in serum samples [24].
The severity of CAP was assessed using the Pneumonia
Severity Index (PSI) [25]. The clinical stability of the patient
was deﬁned on the basis of an approach described by Halm
et al. [26]. Death, transfer to the intensive-care unit (ICU)
and empyema were deﬁned as complications.
CRP levels were determined by an immunoturbidometric
method (Tina-quant) on a Hitachi 917 automated biochem-
istry analyser (Roche Diagnostics GmbH, Mannheim, Ger-
many). The CRP levels were studied on admission, on a daily
basis until the rising trend of CRP level turned into a declin-
ing trend, and subsequently as clinically indicated two to ﬁve
times a week during the hospitalization period. In addition,
CRP level was studied at the time of clinical stability. The
CRP level on admission was deﬁned as CRP1, and the CRP
value at the time of clinical stability as CRP2. Patients gave
written informed consent, and the study was approved by
the Ethics Committee of Turku University Central Hospital.
Statistical analysis
The associations of CRP levels with baseline characteristics
other than age were statistically tested using a two-sample
t-test. Associations between age and CRP levels were studied
using Pearson’s correlation coefﬁcient. The two-sample t-test
was also applied with other two group comparisons of the
CRP mean levels. One-way ANOVA with Tukey’s adjustment
in post hoc comparisons was used when comparing more than
two groups for CRP mean levels. In multivariate analysis, when
covariate-adjusted group comparisons were performed, the
analysis was carried out using linear model techniques. Predic-
tive associations of CRP levels and dichotomous clinical classi-
ﬁcations were analysed using logistic regression models and
receiver operating characteristic (ROC) analysis.
Finally, the predictive associations of CRP levels with the
time of stabilization were examined using Cox’s proportional
hazard regression analysis. The quantiﬁcations of the analyses
were performed by giving the mean values or differences in
the mean values in the case of t-test and ANOVA, or by giv-
ing the ORs, speciﬁcity, sensitivity and area under the ROC
curve in the case of logistic analyses, or by giving hazard
ratios. Statistical conﬁdence of these quantiﬁcations was
reported by giving the 95% CIs among the estimates. A sig-
niﬁcance level of 0.05 was used as the limit for signiﬁcance.
Statistical computing was performed with the SAS System for
Windows, Release 9.1.3/2004.
Results
Patients
Of the 384 patients included, 201 were male and 183 female.
The mean age of the patients was 49.8 years (standard devia-
tion (SD) 19.2 years). Various baseline characteristics of the
patients are presented in Table 1. The distributions of the
patients according to PSI classes and aetiological agents are
presented in tables 2 and 3. S. pneumoniae was the only aeti-
ological agent in 95 (24.7%) patients, M. pneumoniae in 36
(9.4%) patients, C. pneumoniae in 24 (6.3%) patients, another
bacterial agent in seven (1.8%) patients, and a respiratory
virus in 27 (7.0%) patients. Two aetiological agents were
identiﬁed in 20 (5.2%) patients, and the aetiology remained
unidentiﬁed in 175 (45.6%) patients. Blood culture was
TABLE 1. Mean levels of C-reactive protein on admission
(CRP1) according to baseline patient characteristics,
bacteraemia, admission to intensive-care unit ICU), and
death
CRP1 (mg/L)
Mean (SD) Range P
Male
Female
(n = 201)
(n = 183)
199 (125)
204 (112)
4–650
1–560
0.641
Underlying disease Yes (n = 167)
No (n = 217)
209 (127)
195 (111)
1–560
9–650
0.260
COPD Yes (n = 17)
No (n = 367)
230 (110)
200 (119)
37–432
1–650
0.309
Asthma Yes (n = 35)
No (n = 349)
185 (128)
203 (118)
1–494
8–650
0.405
Cardiovascular
disease
Yes (n = 70)
No (n = 314)
180 (126)
206 (116)
8–560
1–650
0.092
Alcoholism Yes (n = 15)
No (n = 369)
317 (115)
197 (116)
13–539
1–650
<0.001
Diabetes Yes (n = 28)
No (n = 356)
224 (140)
200 (117)
8–560
1–650
0.300
Other Yes (n = 54)
No (n = 330)
199 (98)
202 (122)
14–494
1–650
0.885
Smoking Yes (n = 125)
No (n = 259)
238 (128)
184 (110)
9–650
1–539
<0.001
Preceding antibiotic Yes (n = 110)
No (n = 274)
178 (91)
211 (127)
1–452
4–650
0.014
Bacteraemia Yes (n = 55)
No (n = 329)
328 (128)
181 (103)
8–650
1–560
<0.001
Pneumococcal bacteraemia Yes (n = 52)
No (n = 55)
337 (126)
238 (135)
8–650
4–528
<0.001
Admission to ICU Yes (n = 35)
No (n = 349)
270 (163)
194 (111)
8–560
1–650
<0.001
Death Yes (n = 13)
No (n = 371)
217 (131)
201 (118)
14–420
1–650
0.998
COPD, chronic obstructive pulmonary disease; SD, standard deviation.
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positive in 55 patients (52 S. pneumoniae, two Staphylococcus
aureus, one Streptococcus pyogenes). Of all patients, 35 (9.1%)
were transferred to the ICU and 13 (3.3%) died during the
hospitalization.
CRP1
The mean CRP1 level was 201 mg/L (SD 119 mg/L)
(range 1–650 mg/L, n = 384). There were signiﬁcant differ-
ences in the mean CRP1 levels between the patients with
alcoholism, smoking or preceding antibiotic treatment as
baseline characteristics and those without these characteris-
tics (Table 1). The association between CRP1 level and age
did not reach statistical signiﬁcance (r = 0.10, p 0.051).
The mean CRP1 level was signiﬁcantly higher among the
patients who were transferred to the ICU than among the
patients who were not (p <0.001) (Table 1). In prediction of
ICU admission, the area under the ROC curve for CRP1 was
0.639 (95% CI 0.520–0.58). Correspondingly, the area under
the ROC curve for PSI was 0.885 (95% CI 0.847–0.923).
No signiﬁcant difference was observed in the mean CRP1
levels between the patients who died and the patients who
survived (p 0.998) (Table 1).
In univariate analysis, signiﬁcant (p <0.001) differences
were observed in CRP1 levels between the patients belong-
ing to different PSI classes (Table 2). The differences in
CRP1 levels were also signiﬁcant (p <0.001) when PSI groups I
and II combined were compared with PSI groups III–V
combined.
In multivariate analysis, the differences between the PSI
groups remained signiﬁcant after adjustment for age, sex,
cardiovascular disease, bacteraemic pneumonia and aetiologi-
cal agents (p 0.004). In pairwise comparison of the groups,
signiﬁcant differences in CRP1 levels were observed only
between PSI class V and either PSI class I (p 0.002) or PSI
class II (p 0.022). The difference in CRP1 levels was also sig-
niﬁcant (p 0.023) when PSI groups I and II combined were
compared with PSI groups III–V combined.
In the logistic regression analysis, an increment of 50 mg/L
of the CRP1 level was associated with a 1.22-fold odds for a
patient to be in PSI classes III–V as compared with being in
classes I and II (OR 1.22, 95% CI 1.11–1.34; p <0.001).
The mean CRP1 levels were signiﬁcantly higher in the
patients with bacteraemic pneumonia than in those with
non-bacteraemic pneumonia (p <0.001). In addition, the dif-
ference was signiﬁcant between the patients with bacterae-
mic and non-bacteraemic pneumococcal pneumonia
(p <0.001) (Table 1).
An increment of 50 mg/L of the CRP1 level was associ-
ated with a 1.67-fold odds for a patient to be bacteraemic
(OR 1.67, 95% CI 1.46–1.92; p <0.001).
TABLE 2. Mean levels of C-reactive protein on admission (CRP1) according to Pneumonia Severity Index (PSI) classes
CRP1 (mg/L)
PSI I
n = 124
PSI II
n = 113
PSI III
n = 59
PSI IV
n = 73
PSI V
n = 15 p
Mean (SD) 163 (88) 200 (104) 232 (139) 220 (140) 320 (126) <0.001
Range 1–445 4–502 8–650 13–560 129–491
PSI I and II combined PSI III–V combined
Mean (SD) 180 (97) 236 (139) <0.001
Range 1–502 8–650
TABLE 3. Comparison of the mean levels of C-reactive protein on admission (CRP1) with respect to the aetiology
of community-acquired pneumonia in 384 patients. Below diagonal, 95% CIs for differences between means; above diagonal,
p-values. Overall ANOVA p-value <0.001 for CRP1 level
CRP1, mg/L (SD)
(range)
Streptococcus
pneumoniae
n = 95
Chlamydophila
pneumoniae
n = 24
Mycoplasma
pneumoniae
n = 36
Respiratory
virus
n = 27
Other agenta
n = 7
Dual
infectionb
n = 20
Unknown
n = 175
S. pneumoniae 291 (142) (4–650) 0.003 <0.001 <0.001 0.452 0.009 <0.001
C. pneumoniae 200 (110) (25–531) 20 to 162 0.200 0.055 1.000 1.000 0.981
M. pneumoniae 133 (53) (28–225) 97 to 219 )16 to 149 0.990 0.562 0.259 0.175
Respiratory virus 113 (71) (12–248) 109 to 245 )1 to 174 )60 to 99 0.310 0.081 0.034
Other agent 210 (84) (70–350) )42 to 202 )145 to 123 )206 to 51 )230 to 35 1.000 0.990
Dual infection 200 (109) (27–445) 14 to 168 )95 to 94 )154 to 20 )178 to 6 )126 to 148 0.987
Unknown 181 (92) (1–560) 70 to 150 )49 to 87 )105 to 10 )132 to )3 )90 to 150 )54 to 93
SD, standard deviation.
aStaphylococcus aureus, three cases; Legionella pneumophila, two cases; Streptococcus pyogenes, one case; Fusobacterium sp., one case.
bS. pneumoniae with a respiratory virus, 11 cases; S. pneumoniae with C. pneumoniae, one case; M. pneumoniae with inﬂuenza A virus, three cases; M. pneumoniae with Haemo-
philus inﬂuenzae, two cases; C. pneumoniae with Staphylococcus aureus, two cases; C. pneumoniae with adenovirus, one case.
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ROC analysis was used to ﬁnd a cut-off point of CRP1
level that could predict bacteraemia with a sensitivity of at
least 75% combined with the best possible speciﬁcity. The
concentration of 230 mg/L was identiﬁed as such a cut-off
point. The CRP1 levels were ‡230 mg/L for 43 of the 55
patients with bacteraemic pneumonia (sensitivity 78%) and
<230 mg/L for 243 of the 324 patients with non-bacteraemic
pneumonia (speciﬁcity 75%) (area under the ROC
curve 0.812). In PSI classes I and II, the sensitivity and speci-
ﬁcity of this cut-off point value were 72% and 80%, respec-
tively (area under the ROC curve 0.783).
Signiﬁcant (p <0.001) differences in mean CRP1 level were
observed between the patients belonging to various aetiolog-
ical groups (Table 3). The CRP1 level was signiﬁcantly higher
in patients with pneumococcal pneumonia than in those with
any other aetiology, except for a bacterial agent other than
M. pneumoniae or C. pneumoniae.
CRP2 and clinical stabilization
The mean CRP2 level was 80 mg/L (SD 52 mg/L)
(range 1–321 mg/L, n = 336). The mean duration between
the admission and the day when the patient was stabilized
was 4.6 days (SD 3.2 days) (range 1–27 mg/L).
Signiﬁcant differences in CRP2 level were observed
between the different PSI classes (p 0.022) and the aetiology
of CAP (p 0.029). In pairwise comparisons of the aetiological
agents, the difference was signiﬁcant only between the
patients with pneumococcal pneumonia and those with
Mycoplasma pneumonia. CRP2 level was not signiﬁcantly
associated with any of the underlying conditions studied (all
p-values ‡0.103), or with the age of the patient (r = 0.05,
p 0.398).
There was a trend for an association between CRP1 level
and the time to reach clinical stability. In the Cox regression
analysis, it was found that for an increment of 50 mg/L of
the CRP1 level, the risk for the patient to remain unstabi-
lized increased by 6% (hazard ratio 1.06, 95% CI 1.02–1.11;
p 0.005).
CRP during the follow-up
The CRP levels during the ﬁrst 5 days of hospitalization
regarding the different PSI classes, aetiology of CAP, bacte-
raemic and non-bacteraemic disease and the development of
complications are given in Fig. 1.
The median time to reach clinical stability was 4 days. Of
all 384 patients, 23 were discharged, four died, and three
were transferred to another hospital in <4 days after admis-
sion. On day 4 after admission, the CRP level was examined
in 272 (76.8%) of the remaining 354 patients. The risk of
being admitted to the ICU or the need to change the initial
antimicrobial treatment was signiﬁcantly higher in the
patients with CRP levels >100 mg/L on day 4 after admission,
and a signiﬁcantly smaller number of these patients than of
those whose CRP levels were £100 mg/L had been stabilized
at that time-point (Table 4). The CRP level was >100 mg/L
in all four patients who developed empyema.
Discussion
In this study, we analysed the utility of CRP in the evaluation
of patients with CAP, focusing particularly on disease sever-
ity. In this respect, the positive correlation between high
CRP levels and severe disease was one of the main ﬁndings
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FIG. 1. The mean levels of C-reactive
protein (CRP) in patients with commu-
nity-acquired pneumonia on admission
and during the ﬁrst 5 days of hospital-
ization with regard to the different Pne-
umonia Severity Index (PSI) classes (a),
the aetiology (b), bacteraemic and non-
bacteraemic disease (c), and the devel-
opment of complications (d). Numbers
of observations: 384 on day 0 (admis-
sion), 371 on day 1, 343 on day 2, 323
on day 3, 272 on day 4, and 233 on da-
y 5. ICU, intensive-care unit.
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here. This was manifested by the signiﬁcantly higher CRP1
levels in patients who were transferred to the ICU than in
those who were not, as well as by the signiﬁcant association
between the CRP1 levels and different PSI classes. Moreover,
the CRP1 levels in PSI classes I and II combined differed sig-
niﬁcantly from those in PSI classes III–V combined. These are
clinically the two most important groups to be differentiated,
as the mortality risk and the ICU admission rates are known
to be highest in high PSI classes [25,27–29].
According to several studies, mortality and admission
rates to the ICU are higher in patients with bacteraemic
pneumonia than in those with non-bacteraemic pneumonia
[29–31]. Consequently, it is vitally important that patients
with bacteraemia are rapidly recognized, as they should be
admitted to hospital. In the present study, bacteraemic
patients had signiﬁcantly higher CRP1 levels than non-
bacteraemic patients. A cut-off point of 230 mg/L CRP1
predicted bacteraemia with a sensitivity of 78% and a speci-
ﬁcity of 75%. The use of this cut-off point may be especially
useful in patients belonging to PSI classes I and II, for
whom outpatient treatment is commonly considered to be
appropriate [25,32]. High CRP levels on admission should
arouse a suspicion of bacteraemia even in this group of
patients. In the present work, the CRP1 level was
>230 mg/L in 13 (72%) of the 18 bacteraemic patients in
PSI classes I and II.
Procalcitonin measurements were not used here. In previ-
ous studies, procalcitonin has not been shown to be superior
to CRP as a diagnostic marker in community-aquired infec-
tions but has seemed to be a better marker of bacteraemia
[4,33].
In addition, CRP proved valuable as a follow-up test: the
CRP levels fell rapidly in accordance with the clinical recov-
ery of the patient. This is in line with the few previous stud-
ies, in which the usefulness of CRP level as a follow-up test
was evaluated [16,20,22,34,35]. An important ﬁnding in our
patients was that the CRP level of >100 mg/L on day 4 after
admission was suggestive of a treatment failure or develop-
ment of complications. It is of note that only 19% of the
patients with CRP levels >100 mg/L on day 4 had been stabi-
lized, and 21% of them needed treatment in the ICU.
As far as we know, the present study is the ﬁrst to evalu-
ate the CRP level at the time of clinical stabilization, and
shows a signiﬁcant association between CRP2 level and PSI
classes. The signiﬁcant association observed between CRP1
level and the length of the time to reach clinical stability fur-
ther substantiates the connection between high CRP levels
and severe disease.
Previous studies evaluating the behaviour of CRP with
respect to the aetiology of CAP have yielded somewhat
inconsistent results. A few studies have found no difference
in the CRP levels between different aetiologies [16,17],
whereas others have found signiﬁcantly higher CRP levels
only in bacteraemic pneumococcal pneumonia [14,15]. In
one study, the CRP levels were signiﬁcantly higher in L. pneu-
mophila pneumonia than in any other group [18]. In another
study, signiﬁcantly higher CRP levels were detected in pneu-
mococcal pneumonia or L. pneumophila pneumonia than in
other aetiological groups [11]. Here, CRP1 levels in pneumo-
coccal pneumonia differed signiﬁcantly from those in all
other aetiologies except for a bacterial agent other than
M. pneumoniae and C. pneumoniae. Although signiﬁcant differ-
ences in the CRP1 levels between the different causative
agents were observed, the range within each group was
wide, with the lowest values <80 mg/L and the highest values
>200 mg/L. The high variation and large overlap in the values
of the patients with different microbial pathogens indicate
that the CRP concentration is not reliable for guiding deci-
sions regarding the aetiology of CAP in a clinical setting.
In conclusion, our results show that the CRP test may be
valuable as a tool with which to reveal the development of
complications during the treatment of CAP. The positive
TABLE 4. Comparison between
patients with community-acquired
pneumonia who had C-reactive
protein (CRP) levels £100 mg/L and
>100 mg/L on day 4 after admission
CRP £100 mg/L
n = 172
CRP >100 mg/L
n = 100 p
CRP missing
n = 82
Mean duration of hospitalization,days
(SD) (range)
7.2 (4.0) (4–36) 13.1 (7.8) (6–42) <0.001 8.2 (4.4) (4–29)
Patients clinically stabilized 130 (75.6) 19 (19.0) <0.001 56 (68.3)
Patients admitted to the ICU 12 (7.0)a 21 (21.0)b <0.001 2 (2.4)
Change of antimicrobial treatment 41 (23.8) 63 (63.0) <0.001 13 (15.8)
Death 4 (2.3)c 4 (4.0)d 0.425 2 (2.4)d
Empyema 0 4 (4.0) 0.008 0
Data are number (%) of patients, unless otherwise indicated.
ICU, intensive-care unit.
aNone of the patients was admitted to the ICU later than day 4.
bTwo patients were admitted to the ICU later than day 4.
cTwo patients died on day 4 and two patients later.
dAll patients died later than day 4.
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correlation observed between high CRP levels and serious
illness suggests that this biomarker may also be useful for
assessing disease severity in patients with CAP. Towards this
end, the determination of CRP is complementary to, but
cannot substitute for, assessment of the PSI. In our patients,
high CRP levels were associated with a failure to reach clini-
cal stability. The results presented here show that the CRP
test is not reliable for assessing the aetiology of CAP in an
individual patient.
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